Hepatitis C is a viral infection that affects the liver and can lead to chronic inflammation, cirrhosis, and other complications. One of the most frequent haematological issues seen in these patients is a decrease in platelet count, known as thrombocytopenia. Platelets play a vital role in blood clotting, and their reduction can cause an increased risk of bleeding, bruising, and prolonged recovery from minor injuries. Managing low platelet levels in Hepatitis C patients requires a careful balance between treating the underlying liver disease and ensuring safe platelet production and function.
Understanding the Link Between Hepatitis C and Low Platelets
The low platelet count in Hepatitis C occurs primarily due to liver damage and the body’s immune response to the virus. The liver produces thrombopoietin, a hormone responsible for stimulating platelet production in the bone marrow. When the liver becomes inflamed or scarred due to chronic infection, this process slows down.
Additionally, the spleen, which often becomes enlarged (a condition called splenomegaly) in chronic liver disease, traps more platelets than usual. This further reduces the number of platelets circulating in the bloodstream. Antiviral medications, immune reactions, and interferon-based therapies (used in older Hepatitis C treatments) may also contribute to platelet suppression.
such as Revolade 50mg, and it acts by binding to thrombopoietin receptors on bone marrow cells, stimulating them to produce more platelets.
This therapy is especially useful when platelet levels drop dangerously low, making it difficult for patients to continue or start antiviral treatment safely. However, it should only be used under strict medical supervision, as excessive platelet elevation can lead to blood clots or other complications.
- Platelet Transfusions
In emergencies, such as active bleeding or when platelet counts fall below critical levels, platelet transfusions are performed. This provides temporary relief by replenishing platelet levels directly.
However, this approach is short-lived since transfused platelets have a brief lifespan (usually 7–10 days). Transfusions are typically reserved for patients undergoing invasive procedures or surgeries to minimise bleeding risks.